Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Arvinas Holding Company ( (ARVN) ).
On December 6, 2025, Arvinas, Inc. announced preclinical data for ARV-393, a PROTAC BCL6 degrader, in combination with glofitamab, a CD20×CD3 bispecific antibody, at the 67th American Society of Hematology Annual Meeting. The data demonstrated that the combination significantly enhanced tumor growth inhibition and increased tumor regression rates in a high-grade B-cell lymphoma model compared to either agent alone. These findings suggest mechanistic synergies between ARV-393 and T-cell engagement, supporting the initiation of a Phase 1 clinical trial in 2026 to explore this combination as a chemotherapy-free treatment for diffuse large B-cell lymphoma.
The most recent analyst rating on (ARVN) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Spark’s Take on ARVN Stock
According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.
Arvinas’ overall stock score is primarily impacted by its financial challenges, including declining revenue and ongoing losses. However, positive technical indicators and promising clinical developments provide some optimism. The valuation remains a concern due to negative earnings, but strategic collaborations and a strong cash position offer potential for future growth.
To see Spark’s full report on ARVN stock, click here.
More about Arvinas Holding Company
Arvinas, Inc. is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROTAC platform. The company aims to improve the lives of patients with debilitating and life-threatening diseases by creating drugs that target and degrade disease-causing proteins. Arvinas is advancing several investigational drugs, including ARV-393 for non-Hodgkin lymphoma, ARV-102 for neurodegenerative disorders, ARV-806 for mutated cancers, and vepdegestrant for breast cancer.
Average Trading Volume: 2,436,547
Technical Sentiment Signal: Hold
Current Market Cap: $821.4M
Learn more about ARVN stock on TipRanks’ Stock Analysis page.